Double maintains 1 strategies that include ARCT - Arcturus Therapeutics Holdings, Inc.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
GNOM | 61.89% | $46.47M | 0.5% |
XBI | 61.66% | $4.81B | 0.35% |
ARKG | 60.08% | $1.03B | 0.75% |
IBB | 58.91% | $5.37B | 0.45% |
IWC | 53.35% | $840.86M | 0.6% |
PBE | 52.87% | $226.91M | 0.58% |
BBH | 52.57% | $339.54M | 0.35% |
FBT | 50.97% | $1.02B | 0.54% |
IWO | 50.95% | $11.77B | 0.24% |
IWM | 50.04% | $65.64B | 0.19% |
VTWO | 49.88% | $12.65B | 0.07% |
QQQJ | 49.38% | $625.39M | 0.15% |
PBW | 49.01% | $294.50M | 0.65% |
XPH | 48.99% | $150.58M | 0.35% |
SCHA | 48.89% | $17.61B | 0.04% |
KJUL | 48.34% | $159.39M | 0.79% |
GSSC | 48.25% | $591.16M | 0.2% |
VBK | 48.14% | $19.19B | 0.07% |
SMMD | 48.04% | $1.49B | 0.15% |
SPHB | 48.03% | $423.06M | 0.25% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
RGNX | 52.09% | $456.52M | -28.72% | 0.00% |
MRNA | 51.63% | $13.26B | -72.09% | 0.00% |
NTLA | 51.37% | $1.26B | -50.63% | 0.00% |
ABCL | 51.32% | $1.27B | +35.78% | 0.00% |
RXRX | 51.25% | $2.47B | -25.59% | 0.00% |
DNLI | 50.93% | $2.23B | -33.52% | 0.00% |
BEAM | 50.80% | $2.22B | -14.88% | 0.00% |
CRSP | 50.59% | $5.10B | +3.85% | 0.00% |
ALEC | 50.23% | $171.99M | -68.21% | 0.00% |
ARWR | 49.41% | $2.60B | -33.24% | 0.00% |
IDYA | 49.26% | $2.00B | -42.45% | 0.00% |
PDSB | 49.10% | $59.42M | -66.49% | 0.00% |
COHU | 49.10% | $957.96M | -41.53% | 0.00% |
BNTX | 47.81% | $27.39B | +34.50% | 0.00% |
PGEN | 47.58% | $563.79M | +16.46% | 0.00% |
RNA | 46.58% | $3.79B | -28.98% | 0.00% |
SSD | 46.53% | $7.03B | -4.88% | 0.67% |
CLDX | 46.49% | $1.51B | -40.97% | 0.00% |
CRBU | 46.32% | $161.83M | -7.45% | 0.00% |
CRNX | 46.30% | $3.00B | -39.42% | 0.00% |
SeekingAlpha
Arcturus has made progress in cost-cutting and focusing on CF and OTC deficiency. Click here to find out the factors that make ARCT a sell-rated stock.
Yahoo
SAN DIEGO, June 30, 2025--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announces positive Phase 2 interim results in people with OTC deficiency treated with ARCT-810, an mRNA therapeutic candidate designed to replace the OTC enzyme and restore urea cycle activity preventing hyperammonemia crise
Finnhub
Arcturus Therapeutics Holdings Inc. announced positive Phase 2 interim results in people with OTC deficiency treated with ARCT-810, an mRNA therapeutic candidate designed to replace the OTC enzyme and...
Finnhub
Presentation Operator MessageOperator Greetings, and welcome to the Arcturus Therapeutics key opinion leader, KOL presentation to discuss ARCT-810 Phase II interim data for OTC deficiency.
Finnhub
SAN DIEGO - Arcturus Therapeutics Holdings Inc. , a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory...
Yahoo
SAN DIEGO, June 23, 2025--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will host a virtual KOL presentation of ARCT-810 Phase 2 interim data for Ornithine Transcarbamylase (OTC) deficiency on Monday, June 30, 2025, at 12:00 p.m. ET. The Company will issue a press release summa
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IBTI | 0.03% | $1.06B | 0.07% |
TDTT | 0.06% | $2.63B | 0.18% |
BSCP | 0.14% | $3.25B | 0.1% |
UGA | 0.15% | $76.33M | 0.97% |
SHV | 0.24% | $20.59B | 0.15% |
IBTJ | 0.35% | $686.15M | 0.07% |
STIP | -0.60% | $12.68B | 0.03% |
UDN | 0.61% | $147.46M | 0.78% |
IEI | 0.62% | $15.53B | 0.15% |
TBLL | -0.67% | $2.12B | 0.08% |
DBE | 0.80% | $54.61M | 0.77% |
AGZ | 0.88% | $609.66M | 0.2% |
LDUR | 0.88% | $922.12M | 0.5% |
FXE | 0.92% | $588.06M | 0.4% |
GSST | 0.94% | $920.88M | 0.16% |
FTSD | -0.98% | $233.11M | 0.25% |
SHY | -0.99% | $23.54B | 0.15% |
BSMW | 1.09% | $107.49M | 0.18% |
BILZ | 1.14% | $851.85M | 0.14% |
SHYM | -1.15% | $355.86M | 0.35% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -44.72% | $315.93M | 1.43% |
VIXY | -36.01% | $184.73M | 0.85% |
TAIL | -30.47% | $94.86M | 0.59% |
IVOL | -13.09% | $342.69M | 1.02% |
ULST | -11.62% | $592.38M | 0.2% |
TPMN | -9.68% | $31.06M | 0.65% |
CLIP | -8.56% | $1.55B | 0.07% |
XONE | -8.35% | $628.85M | 0.03% |
GBIL | -8.02% | $6.36B | 0.12% |
FXY | -7.49% | $802.69M | 0.4% |
TFLO | -7.23% | $6.74B | 0.15% |
XHLF | -6.67% | $1.73B | 0.03% |
CTA | -6.49% | $1.08B | 0.76% |
BILS | -6.09% | $3.80B | 0.1356% |
IBTH | -5.94% | $1.62B | 0.07% |
SGOV | -5.61% | $50.93B | 0.09% |
SCHO | -5.60% | $10.98B | 0.03% |
UNG | -5.57% | $375.27M | 1.06% |
UTWO | -5.53% | $376.33M | 0.15% |
IBTG | -5.29% | $1.92B | 0.07% |
Current Value
$14.161 Year Return
Current Value
$14.161 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
SBS | <0.01% | $13.75B | +30.48% | 3.28% |
MSEX | 0.01% | $997.80M | -1.54% | 2.41% |
DFDV | 0.01% | $363.21M | +2,422.23% | 0.00% |
STG | 0.06% | $38.79M | -3.01% | 0.00% |
IMNN | -0.07% | $13.21M | -54.55% | 0.00% |
VZ | 0.13% | $177.21B | +1.77% | 8.05% |
AMT | -0.34% | $103.46B | +6.67% | 3.01% |
HMY | -0.36% | $8.95B | +43.66% | 1.20% |
VIV | 0.36% | $18.60B | +32.81% | 0.67% |
DOGZ | 0.44% | $117.12M | -40.72% | 0.00% |
VSTA | -0.57% | $325.62M | +30.97% | 0.00% |
HSY | 0.62% | $33.36B | -11.86% | 3.35% |
INFA | 0.69% | $7.40B | -13.43% | 0.00% |
BTCT | -0.71% | $28.19M | +79.43% | 0.00% |
PGR | 0.73% | $146.19B | +17.73% | 1.98% |
ALL | -0.75% | $51.55B | +20.14% | 1.98% |
EZPW | 0.76% | $760.29M | +36.43% | 0.00% |
CAG | 0.81% | $9.30B | -31.32% | 7.20% |
TIMB | 0.93% | $9.35B | +26.49% | 2.11% |
HUM | 1.02% | $28.02B | -38.86% | 1.54% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CBOE | -18.19% | $24.55B | +38.09% | 1.08% |
MO | -12.69% | $98.62B | +24.36% | 7.00% |
NOC | -11.81% | $73.96B | +18.95% | 1.66% |
ED | -10.34% | $36.42B | +10.51% | 3.36% |
MKTX | -10.08% | $8.21B | +2.36% | 1.37% |
CL | -9.83% | $73.44B | -7.30% | 2.25% |
LITB | -9.73% | $24.26M | -71.62% | 0.00% |
KR | -9.43% | $46.75B | +34.05% | 1.81% |
UNH | -8.35% | $271.70B | -40.62% | 2.85% |
K | -8.33% | $27.64B | +40.17% | 2.86% |
CME | -7.95% | $99.17B | +44.04% | 1.75% |
CYCN | -7.65% | $11.40M | +5.03% | 0.00% |
KMB | -6.93% | $43.78B | -6.43% | 3.77% |
PM | -6.45% | $281.71B | +72.37% | 3.01% |
CNC | -6.44% | $16.18B | -51.64% | 0.00% |
DUK | -6.40% | $91.85B | +13.12% | 3.57% |
BTI | -5.94% | $111.18B | +57.68% | 6.01% |
GFI | -5.01% | $21.43B | +47.60% | 2.33% |
DRD | -4.69% | $1.15B | +38.33% | 2.06% |
EXC | -4.48% | $44.05B | +23.53% | 3.60% |